Method and device for radiotherapy

US10058713B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10058713-B2
Application numberUS-201414551273-A
CountryUS
Kind codeB2
Filing dateNov 24, 2014
Priority dateApr 30, 2003
Publication dateAug 28, 2018
Grant dateAug 28, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the radionuclide to administering a predetermined therapeutic dose of decay chain nuclei and alpha particles into the tumor.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of manufacturing a radiotherapy device, the method comprising: providing a probe having a surface, and adapted for being at least partially introduced into a body of a subject; positioning said surface in a flux of a radionuclide selected from the group consisting of Radium-223 and Radium-224; and collecting atoms of said radionuclide to retainably embed said atoms on or beneath said surface, in a manner that a natural recoil energy of daughter nuclei of the radionuclide is sufficient to allow the daughter nuclei to escape the surface, so that said radionuclide remains in said probe while a therapeutic dose of decay chain nuclei and alpha particles of said radionuclide is emitted outside said surface, thereby manufacturing the radiotherapy device; and coating said surface by a protective coat. 2. The method of claim 1 , wherein said collecting is by direct implantation in a vacuum. 3. The method of claim 1 , wherein said collecting is by connecting said surface to a voltage source of negative polarity. 4. The method of claim 3 , wherein said positioning of said surface in said flux of said radionuclide is in a gaseous environment. 5. The method of claim 3 , wherein a pressure of said gaseous environment and a voltage of said voltage source are selected such that a velocity of nuclei is reduced to a thermal velocity. 6. The method of claim 1 , wherein said probe is selected such that the device is removably implantable in a body of a subject. 7. The method of claim 1 , wherein said probe comprises at least one needle. 8. The method of claim 1 , wherein said probe comprises at least one bead. 9. The method of claim 1 , wherein said probe is a tip of an endoscope. 10. The method of claim 1 , wherein said probe is a tip of a laparoscope. 11. The method of claim 1 , wherein said probe is a tip of an imaging device. 12. The method of claim 1 , wherein said probe comprises an inner elongated member and an outer tubular member having a mouth section configured for receiving said inner elongated member, said inner elongated member being movable within said outer tubular member and having a distal end and a proximal end, whereby said radionuclide is collected on or beneath a surface of said distal end. 13. The method of claim 1 , wherein at least one of a thickness and a material of said protective coat is selected so as not to prevent emission of decay chain nuclei and alpha particles from said surface of said probe. 14. The method of claim 1 , wherein said probe is capable of administering from about 100 rem to about 100000 rem of radiation dose. 15. The method of claim 1 , wherein an activity of said radionuclide is from about 10 nanoCurie to about 10 microCurie. 16. The method of claim 1 , wherein the probe comprises an elongated member. 17. The method of claim 16 , wherein the probe comprises a tubular member. 18. The method of claim 1 , wherein the protective coat has a thickness of about 5 nanometers. 19. The method of claim 1 , wherein providing the probe comprises providing a probe having an outer layer made of a porous material. 20. The method of claim 1 , wherein collecting atoms of the radionuclide to retainably embed the atoms on or beneath the surface comprises collecting atoms of the radionuclide to retainably embed the atoms at a depth of the order of about 10 nanometers. 21. The method of claim 1 , wherein collecting the atoms comprises collecting the atoms on or beneath said surface, with a surface density of between about 10 10 to about 10 13 atoms/cm 2 .

Assignees

Inventors

Classifications

  • A61N5/1015Primary

    Treatment of resected cavities created by surgery, e.g. lumpectomy · CPC title

  • Interstitial radiation therapy · CPC title

  • Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents · CPC title

  • Arrangements or means for the introduction of sources into the body · CPC title

  • using radiation sources introduced into or applied onto the body; brachytherapy · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10058713B2 cover?
A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the radionuclide to administering a predetermined t…
Who is the assignee on this patent?
Althera Medical Ltd, Alpha Tau Medical Ltd
What technology area does this patent fall under?
Primary CPC classification A61N5/1015. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).